Annual Total Liabilities
$9.37 M
+$358.00 K+3.97%
March 31, 2024
Summary
- As of February 25, 2025, VTGN annual total liabilities is $9.37 million, with the most recent change of +$358.00 thousand (+3.97%) on March 31, 2024.
- During the last 3 years, VTGN annual total liabilities has fallen by -$6.94 million (-42.54%).
- VTGN annual total liabilities is now -54.99% below its all-time high of $20.81 million, reached on March 31, 2015.
Performance
VTGN Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$11.19 M
+$1.66 M+17.46%
December 31, 2024
Summary
- As of February 25, 2025, VTGN quarterly total liabilities is $11.19 million, with the most recent change of +$1.66 million (+17.46%) on December 31, 2024.
- Over the past year, VTGN quarterly total liabilities has increased by +$2.44 million (+27.90%).
- VTGN quarterly total liabilities is now -46.26% below its all-time high of $20.81 million, reached on March 31, 2015.
Performance
VTGN Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
VTGN Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +4.0% | +27.9% |
| 3 y3 years | -42.5% | +27.9% |
| 5 y5 years | +35.0% | +27.9% |
VTGN Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -42.5% | +4.0% | -11.8% | +70.8% |
| 5 y | 5-year | -42.5% | +35.0% | -43.6% | +70.8% |
| alltime | all time | -55.0% | >+9999.0% | -46.3% | >+9999.0% |
VistaGen Therapeutics Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | - | $11.19 M(+17.5%) |
| Sep 2024 | - | $9.52 M(+8.9%) |
| Jun 2024 | - | $8.74 M(-6.6%) |
| Mar 2024 | $9.37 M(+4.0%) | $9.37 M(+20.3%) |
| Dec 2023 | - | $7.78 M(+18.8%) |
| Sep 2023 | - | $6.55 M(-20.0%) |
| Jun 2023 | - | $8.18 M(-9.2%) |
| Mar 2023 | $9.01 M(-9.3%) | $9.01 M(-0.3%) |
| Dec 2022 | - | $9.03 M(-18.6%) |
| Sep 2022 | - | $11.10 M(-12.4%) |
| Jun 2022 | - | $12.67 M(+27.7%) |
| Mar 2022 | $9.93 M(-39.1%) | $9.93 M(-6.0%) |
| Dec 2021 | - | $10.56 M(-46.8%) |
| Sep 2021 | - | $19.84 M(+8.5%) |
| Jun 2021 | - | $18.29 M(+12.2%) |
| Mar 2021 | $16.30 M(+41.7%) | $16.30 M(+5.4%) |
| Dec 2020 | - | $15.46 M(-3.7%) |
| Sep 2020 | - | $16.05 M(+36.2%) |
| Jun 2020 | - | $11.78 M(+2.4%) |
| Mar 2020 | $11.50 M(+65.8%) | $11.50 M(+0.7%) |
| Dec 2019 | - | $11.43 M(-7.6%) |
| Sep 2019 | - | $12.37 M(+9.2%) |
| Jun 2019 | - | $11.32 M(+63.2%) |
| Mar 2019 | $6.94 M(+59.0%) | $6.94 M(+19.0%) |
| Dec 2018 | - | $5.83 M(+19.0%) |
| Sep 2018 | - | $4.90 M(-2.7%) |
| Jun 2018 | - | $5.03 M(+15.4%) |
| Mar 2018 | $4.36 M(+40.9%) | $4.36 M(+9.6%) |
| Dec 2017 | - | $3.98 M(-7.2%) |
| Sep 2017 | - | $4.29 M(+40.9%) |
| Jun 2017 | - | $3.04 M(-1.7%) |
| Mar 2017 | $3.10 M | $3.10 M(-5.8%) |
| Dec 2016 | - | $3.29 M(+12.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2016 | - | $2.94 M(+13.1%) |
| Jun 2016 | - | $2.60 M(-34.6%) |
| Mar 2016 | $3.97 M(-80.9%) | $3.97 M(+9.9%) |
| Dec 2015 | - | $3.61 M(+10.8%) |
| Sep 2015 | - | $3.26 M(-29.3%) |
| Jun 2015 | - | $4.61 M(-77.9%) |
| Mar 2015 | $20.81 M(+59.3%) | $20.81 M(+15.4%) |
| Dec 2014 | - | $18.04 M(+1.6%) |
| Sep 2014 | - | $17.76 M(+9.9%) |
| Jun 2014 | - | $16.16 M(+23.7%) |
| Mar 2014 | $13.06 M(-2.8%) | $13.06 M(+8.9%) |
| Dec 2013 | - | $12.00 M(-8.8%) |
| Sep 2013 | - | $13.16 M(+6.3%) |
| Jun 2013 | - | $12.38 M(-7.9%) |
| Mar 2013 | $13.44 M(+122.2%) | $13.44 M(+23.9%) |
| Dec 2012 | - | $10.85 M(+57.6%) |
| Sep 2012 | - | $6.88 M(-0.7%) |
| Jun 2012 | - | $6.93 M(+14.6%) |
| Mar 2012 | $6.05 M(>+9900.0%) | $6.05 M(+17.1%) |
| Dec 2011 | - | $5.16 M(-44.3%) |
| Sep 2011 | - | $9.26 M(+5.8%) |
| Jun 2011 | - | $8.75 M(>+9900.0%) |
| Mar 2011 | - | $6700.00(+109.4%) |
| Dec 2010 | $3200.00(+113.3%) | $3200.00(-5.9%) |
| Sep 2010 | - | $3400.00(+126.7%) |
| Jun 2010 | - | $1500.00(-64.3%) |
| Mar 2010 | - | $4200.00(+180.0%) |
| Dec 2009 | $1500.00(-44.4%) | $1500.00(-44.4%) |
| Sep 2009 | - | $2700.00(+80.0%) |
| Jun 2009 | - | $1500.00(-44.4%) |
| Dec 2008 | $2700.00 | $2700.00(-27.0%) |
| Jun 2008 | - | $3700.00(+37.0%) |
| Mar 2008 | - | $2700.00 |
FAQ
- What is VistaGen Therapeutics annual total liabilities?
- What is the all time high annual total liabilities for VistaGen Therapeutics?
- What is VistaGen Therapeutics annual total liabilities year-on-year change?
- What is VistaGen Therapeutics quarterly total liabilities?
- What is the all time high quarterly total liabilities for VistaGen Therapeutics?
- What is VistaGen Therapeutics quarterly total liabilities year-on-year change?
What is VistaGen Therapeutics annual total liabilities?
The current annual total liabilities of VTGN is $9.37 M
What is the all time high annual total liabilities for VistaGen Therapeutics?
VistaGen Therapeutics all-time high annual total liabilities is $20.81 M
What is VistaGen Therapeutics annual total liabilities year-on-year change?
Over the past year, VTGN annual total liabilities has changed by +$358.00 K (+3.97%)
What is VistaGen Therapeutics quarterly total liabilities?
The current quarterly total liabilities of VTGN is $11.19 M
What is the all time high quarterly total liabilities for VistaGen Therapeutics?
VistaGen Therapeutics all-time high quarterly total liabilities is $20.81 M
What is VistaGen Therapeutics quarterly total liabilities year-on-year change?
Over the past year, VTGN quarterly total liabilities has changed by +$2.44 M (+27.90%)